Topic: Leland Wilson
One of the "highlights" from diet pill maker Vivus' (VVUS) just-released quarterly earnings announcement states that the company has completed...
VIVUS, Inc. (VVUS) Q3 2010 Earnings Call November 08, 2010 4:30 pm ET. There are no guarantees that our response to the FDA with the CRL will be sufficient to satisfy FDAs safety concern, and that the FDA will not require ...
VIVUS Inc. (VVUS) Q2 2010 Earnings Call Transcript August 02, 2010 4:30 pm ET. On today's call we will summarize our thoughts regarding the recent endocrinologic and metabolic drug advisory committee meeting for Qnexa. Peter will also provide an update ...
VIVUS, Inc. (VVUS) Q1 2010 Earnings Call May 03, 2010 5:30 pm ET. First, we previously announced that the Endocrinologic and Metabolic Drug Advisory Committee has tentatively scheduled to review the company's new drug application for Qnexa on July 15th ...
Biotech firm Vivus unveiled a would-be player Monday in the 3.7-billion-dollar erectile dysfunction market: avanafil, effective in just 15 minutes, far faster than blockbuster rivals Viagra and Cialis. "The magnitude of success in the first 15 minutes was surprising," Leland Wilson ...
VIVUS Inc. (VVUS) Q2 2008 Earnings Call August 04, 2008 4:30 pm ET. Clearly the highlights of the second quarter was the presentation of the results of the OB0202 study, the primary end point of this trial was a reduction in ...
VIVUS Inc. (VVUS) Q1 2008 Earnings Call May 08, 2008 4:30 pm ET. Third, we completed dosing in the six-month OB-202 study and initiated its six-month extension of the OB-202 study, the study of Qnexa in Type II diabetics. The studies ...
